A new therapeutic approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum

Journal of Obstetrics and Gynaecology Research

Volumn 29, Issue 3, 2003, Pages 123-131

  Sehouli, Jalid ^a   Stengel, Dirk ^b   Oskay, Gülten ^a   Blohmer, Jens ^a   Kaubitzsch, Sabine ^a   Lichtenegger, Werner ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Chemotherapy; Gemcitabine; Ovarian cancer; Topotecan

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; GEMCITABINE; PACLITAXEL; PLATINUM; SEROTONIN 3 ANTAGONIST; TOPOTECAN; VISCUM ALBUM LECTIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT FAILURE; CHEMICALLY INDUCED DISORDER; MORTALITY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FEMALE; HUMANS; LEUKOPENIA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; SURVIVAL RATE; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT FAILURE;

EID: 0037968836     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1341-8076.2003.00087.x     Document Type: Article

References (44)

1. Ferlay JF, Pisani P, Parkin DM. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC Cancerbase No. 5. Lyon: IARCPress, 2001.
2. Berek JS, Bertelsen K, Du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10 (Suppl.): 87-92.
3. Lichtenegger W, Sehouli J, Buchmann E. Operative results after primary and secondary debulking-operations in advanced ovarian cancer. J Obstet Gyn Res 1998; 24: 447-451.
4. McGuire PW, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
5. Du Bois A, Lueck HJ, Meier W. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial. Proceedings of the American Society of Clinical Oncology 1999; 19, abstract 1374.
6. McGuire PW & Ozols RF. Chemotherapy of advanced ovarian cancer. Seminars Oncol 1998; 25: 340-348.
7. Ozols RF, Bundy BN, Fowler J. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) vs carboplatin (CARBO)/paclitaxel (PAC) in optimal Stage III epithelial ovarian cancer (GOG 158). Proceedings of the American Society of Clinical Oncology 1999; 18, abstract 1373.
8. Neijt JP. Ovarian Cancer: Rethinking Prognostic Factors and Chemotherapy. ASCO Educational Book. San Francisco: Oxford University Press, 1994, 214-220.
9. McGuire PW. Primary Therapy of Epithelial Ovarian Cancer. ASCO Educational Book. San Francisco: Oxford University Press, 2001, 477-480.
10. Conte PF, Gadducci A, Cianci C. Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 2001; 11 (S1): 52-56.
11. Knopf K, Brown M, Kohn EC. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer, 1980-1997. ASCO Proceedings 1998; 17: abstract 1385, 359.
12. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
13. Walle U, Sehouli J, Stengel D et al. on behalf of the NOGGO Study Group, Charite. Virchow University Hospital, Berlin, Germany. Development of a Symptom-Check-List for patients with advanced ovarian cancer. Results from a phase I and II clinical trial. Proceedings of ASCO 2001 20: abstract 2531.
14. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352.
15. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. Int J Gynecol Cancer 2001; 11: (S1): 42-51.
16. Del Bino G, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camphothecin. Exptl Cell Res 1991; 193: 27-35.
17. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056-3061.
18. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-1557.
19. Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193.
20. Gore M, Ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001; 19: 1893-1900.
21. Von Hoff DD, Burris HA, Eckardt J. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 1994; 34 (Suppl.): 41-45.
22. Ganem G, Gladieff L, Guastalla JP. Sequential topotecan and etoposid in pretreated ovarian cancer: A GINECO phase II study. Proceedings of ASCO 1998; 18: abstract 1371.
23. Madhusudan S & Deplanque G, Levitt NA. A phase I study of sequential topotecan and infusional etoposide phosphate in recurrent ovarian cancer. Proceedings of ASCO 2001; 21: abstract 871.
24. Rowinsky EK, Kaufmann SH, Baker SD et al. Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-3084.
25. Sehouli J, Lichtenegger W, Schnborn J. Phase I trial of topotecan in combination with gemcitabine in platinum and paclitaxel refractory ovarian cancer. Proceedings of ASCO 1999; 18: abstract 1482.
26. Vannetzel JM, Fabbro M, Weber B. Topotecan (T) and cyclophosphamide (Cy) in second line treatment of advanced ovarian cancer (AOC): A GINECO phase II trial. Proceedings of ASCO 2001; 20: abstract 811.
27. Hertel L, Boder GB, Kroin JS. Evaluation of the antitumor activity of gemcitabine. Cancer Res 1990; 50: 4417-4422.
28. Morant R. Phase II study: Gemcitabine in refractory metastatic prostatic carcinoma. Proceedings of ASCO 1997; 16: abstract 1109.
29. Hansen SW, Anderson H, Boman K, Hansen MI. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proceedings of the Ann Meet Am Soc Clin Oncol 1999; 18: abstract 1395.
30. Lund B, Hensen OP, Theilade K. Phase II study of gemcitabine (2′2′-difluorodeooxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533.
31. Shapiro JD, Millward MJ, Rischin D. Activity of gemcitabine in patients with advanced ovarian cancer. Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
32. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999; 10: 853-855.
33. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma. Proc Am Soc Clin Oncol 2000; 19: (Abstract 28a) 1603.
34. Faries D. Practical modifications of the continual reassessment method for phase 1 cancer clinical trials. J Biopharm 1994; 4: 147-164.
35. National Cancer Institute. Common toxicity criteria. In: Perry MC, eds. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1990, 1133-1140.
36. Distefano M, Ferlini C, De-Vincenzo R, Gaggini C, Manusco S, Scambia G. Antagonistic effect of the combination of gemcitabine/topotecan in ovarian cancer cells. Oncol Res 2001; 12: 355-359.
37. O'Reilly S, Armstrong DK, Grochow LB. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 1997; 67: 329-330.
38. Cole JL, Rinaldi DA, Lormand NA. Phase I trial of topotecan and gemcitabine for patients with previously treated, advanced non-small cell cancer. Proceedings of ASCO 1999; 18: abstract 1930.
39. Dabrow MB, Gilman PB, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic NSCLC. Proceedings of ASCO 1999; 18: abstract 1930.
40. Laufmann LR, Spiiiridonidis CH, Jones JJ. Gemcitabine and topotecan - A Phase I trial. Proceedings of ASCO 1999; 18: abstract 837.
41. Sun W, Stevenson JP, Gallagher M et al. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001; 92: 414-419.
42. Greggi S, Salerno MG, D'Agostino G et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 2001; 60: 19-23.
43. Sorensen M, Jensen PB, Herrstedt H et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol 2000; 11: 829-835.
44. Sehouli J, Stengel D, Oskay G et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002; 13: 1749-1755.